Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
finasteride long-acting injectable
- Development stage
- Phase 2
- Lead developer
- Daewoong Pharmaceutical
- Modality
- Small Molecules
- Administration
- Subcutaneous
01
Overview
A long-acting injectable (LAI) formulation of finasteride encapsulated within poly lactic-co-glycolic acid microspheres, designed for the treatment of androgenetic alopecia (AGA). This novel formulation maintains stable blood concentrations for over a month without initial burst release, providing consistent DHT suppression comparable to daily oral finasteride.
- Other names
- finasteride controlled release injectionfinasteride loaded microspherefinasteride long acting injection formulationfinasteride subcutaneous injectionfinasteride sustained release injection
02
Targets
SRD5A1 (Steroid 5-alpha-reductase type 1)SRD5A2 (Steroid 5-alpha-reductase type II)SRD5A (Steroid 5-alpha-reductase)
Beyond the preview
Go deeper on finasteride long-acting injectable.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on finasteride long-acting injectable.